Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Core Binding Factor Acute Myeloid Leukemia (CBF-AML)”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Testing effectiveness (Phase 2)Ended earlyNCT03686345
What this trial is testing

Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia

Who this might be right for
Core Binding Factor Acute Myeloid Leukemia (CBF-AML)
Niguarda Hospital 34
Testing effectiveness (Phase 2)UnknownNCT01146977
What this trial is testing

Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)

Who this might be right for
Acute Myeloid Leukemia
Cooperative Study Group A for Hematology 43
Testing effectiveness (Phase 2)Looking for participantsNCT06316960
What this trial is testing

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Who this might be right for
AML, ChildhoodRelapse/RecurrenceRefractory AML+2 more
Children's Hospital of Soochow University 50
Not applicableUnknownNCT01066286
What this trial is testing

Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia

Who this might be right for
Myeloid Leukemia
Samsung Medical Center 100
Testing effectiveness (Phase 2)Study completedNCT02113319
What this trial is testing

Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia

Who this might be right for
Acute Myelogenous Leukemia
University Hospital, Angers 27
Testing effectiveness (Phase 2)Study completedNCT01238211
What this trial is testing

Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11+5 more
National Cancer Institute (NCI) 61
Testing effectiveness (Phase 2)Looking for participantsNCT06917911
What this trial is testing

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Who this might be right for
Core Binding Factor Acute Myeloid Leukemia
National Cancer Institute (NCI) 162
Not applicableLooking for participantsNCT06458244
What this trial is testing

The Efficacy of Allo-HSCT in ND HR-CBF-AML

Who this might be right for
Acute Myeloid Leukemia
Ruijin Hospital 90
Post-approval studies (Phase 4)Study completedNCT02926586
What this trial is testing

Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML

Who this might be right for
Acute Myeloid LeukemiaCore-Binding Factor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 68
Testing effectiveness (Phase 2)Looking for participantsNCT00801489
What this trial is testing

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1+7 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00850382
What this trial is testing

Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)
University of Ulm 89
Not applicableStudy completedNCT01050036
What this trial is testing

Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid
Asan Medical Center 20
Not applicableStudy completedNCT05070208
What this trial is testing

Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor

Who this might be right for
Acute Myeloblastic Leukemia Core Binding Factor
Acute Leukemia French Association 400
Early research (Phase 1)WithdrawnNCT02680951
What this trial is testing

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Emory University
Testing effectiveness (Phase 2)UnknownNCT05821738
What this trial is testing

Avapritinib in CBF-AML With KIT Mutations

Who this might be right for
Core Binding Factor Acute Myeloid LeukemiaKIT Mutation-Related Tumors
The First Affiliated Hospital of Soochow University 50
Large-scale testing (Phase 3)Study completedNCT02013648
What this trial is testing

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

Who this might be right for
Acute Myeloid Leukemia (AML)
University of Ulm 204
Large-scale testing (Phase 3)Study completedNCT00428558
What this trial is testing

Timed-Sequential Induction in CBF-AML

Who this might be right for
Acute Myeloid Leukemia
Assistance Publique - Hôpitaux de Paris 200
Testing effectiveness (Phase 2)UnknownNCT05404516
What this trial is testing

Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML

Who this might be right for
Core Binding Factor Acute Myeloid Leukemia
Nanfang Hospital, Southern Medical University 88
270